Engineering 300-nt Circular RNAs to Unfold Pathogenic RNA Structures as a Novel Therapeutic Strategy for Infectious & NonInfectious Diseases
- Reverse structure-driven pathogenicity by applying hybridization-based circRNAs that block the formation of aberrant RNA structures underlying ALS, muscular dystrophies, and viral replication
- Expand circRNA utility well beyond vaccines and protein replacement by demonstrating a new non-canonical mode of action with in vitro and in vivo proof across multiple disease classes
- Strengthen translational readiness through insights into purity thresholds, linear– circular separation, and delivery considerations unique to small, non-coding circRNA modalities